« Back
Home /
Mouse anti-Cleaved PARP1 Monoclonal Antibody

Mouse anti-Cleaved PARP1 Monoclonal Antibody

Item no.	RD85518A-60uL
Manufacturer	Reddot Biotech
Amount	60 uL
Category	Antibodies Primary Antibodies
Type	Antibody Monoclonal
Applications	WB, IF, IHC-P
Clone	6K6
Specific against	Human
Host	Mouse
Isotype	IgG
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Alias	ADP-ribosyltransferase diphtheria toxin-like 1,ADPRT 1,ADPRT,ADPRT1,APOPAIN,ARTD1,NAD(+) ADP-ribosyltransferase 1,PARP,PARP-1,PARP1,PARP1,Poly [ADP-ribose] polymerase 1,Poly ADP ribose polymerase 1,Poly[ADP-ribose] synthase 1,PPOL,SCA1
Available
Background	This gene encodes a chromatin-associated enzyme, poly(ADP-ribosyl)transferase, which modifies various nuclear proteins by poly(ADP-ribosyl)ation. The modification is dependent on DNA and is involved in the regulation of various important cellular processes such as differentiation, proliferation, and tumor transformation and also in the regulation of the molecular events involved in the recovery of cell from DNA damage. In addition, this enzyme may be the site of mutation in Fanconi anemia, and may participate in the pathophysiology of type I diabetes.
Buffer	PBS with 0.02% sodium azide, 50% glycerol, pH7.4
Clonality	Monoclonal
Concentration	1mg/mL
Dilution	WB 1:2000-5000, IHC 1:50-300, IF 1:100-1:300
Immunogen	Synthetic Peptide
Purification_Method	Protein A purification
Storage	Store at -20℃. Avoid repeated freeze / thaw cycles.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 60 uL

available

Delivery expected until 8/23/2024